"Therapeutic antibody discovery and engineering represent a significant market opportunity. It is remarkable that our vision and track record was able to attract top antibody engineers such as Aaron to the team," commented John "Lippy" Lippincott, Ph.D., VP of Antibody Discovery.
"I have been a long-standing client of LakePharma and have always been impressed by their quality and productivity. During my career, I have always loved building and leading teams focused on discovering novel biologics, which aligns well with LakePharma's commitment to build a state-of-the-art antibody center. I look forward to leading LakePharma's expansion into the antibody discovery and engineering space and helping others discover drugs that can help patients," said Aaron Sato, Ph.D., CSO.
Aaron Sato received his doctorate in Biological Chemistry from MIT with 18 years of industry experience. Prior to LakePharma, he held management positions at Dyax, Oncomed and Sutro. He is an author of over 30 peer reviewed papers, 40 issued patents in the antibody space, and is a well-known speaker and organizer in the top scientific conferences.
LakePharma is the leading contract research organization (CRO) specializing in antibody engineering, antibody discovery, molecular engineering, protein chemistry, bioexpression, biofunction, bioprocessing, and bioanalytics. LakePharma focuses on integrated platforms to support projects throughout the drug discovery process. LakePharma offers dedicated client services and sophisticated software to provide real-time access to project data via a secure cloud-based portal. For more information, please visit lakepharma.com
VP Commercial Operations
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/lakepharma-appoints-dr-aaron-sato-as-chief-scientific-officer-to-lead-its-antibody-center-300402806.html
SOURCE LakePharma, Inc.